Cinctive Capital Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

Cinctive Capital Management’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-37,194	Closed	-$490K	–	466
2025 Q4	$490K	Buy	+37,194	New	+$439K	0.03%	331
2025 Q1	–	Sell	-10,576	Closed	-$573K	–	408
2024 Q4	$573K	Buy	+10,576	New	+$540K	0.03%	313
2024 Q3	–	Sell	-10,181	Closed	-$448K	–	460
2024 Q2	$448K	Buy	10,181 +5,968	+142%	+$253K	0.02%	356
2024 Q1	$212K	Buy	+4,213	New	+$229K	0.01%	371
2021 Q1	–	Sell	-10,000	Closed	-$108K	–	469
2020 Q4	$108K	Buy	+10,000	New	+$106K	0.01%	315

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Cinctive Capital Management's MLTX Position: Q1 2026 in Review

Cinctive Capital Management sold out of MoonLake Immunotherapeutics (MLTX) in Q1 2026, closing a stake of 37,194 shares — an estimated $490K sold.

Cinctive Capital Management first reported a position in MLTX in Q4 2020 and held it in 5 quarters. The position peaked at $573K in Q4 2024. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

Cinctive Capital Management reported no remaining MoonLake Immunotherapeutics position as of Q1 2026 after selling out during the quarter.
Cinctive Capital Management sold 37,194 MoonLake Immunotherapeutics shares in Q1 2026, an estimated $490K.
Cinctive Capital Management first reported a position in MoonLake Immunotherapeutics in Q4 2020 and held it in 5 quarters.
Cinctive Capital Management's MoonLake Immunotherapeutics position peaked at $573K in Q4 2024.
147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on Cinctive Capital Management's 13F filing for Q1 2026, filed 15 May 2026.